Shares of Danaher Corporation (DHR) surged 5.58% in pre-market trading on Wednesday, following the company's announcement of raised annual profit forecasts and better-than-expected quarterly results. The life sciences firm is capitalizing on steady demand for bioprocessing from its pharmaceutical clients and a recovery in the Chinese market to drive growth.
The company's strong performance has attracted positive attention from Wall Street analysts. Jefferies reiterated a Buy rating on Danaher with a price target of $230, while Scotiabank maintained its Buy rating with a $275 price target. TD Cowen raised its target price to $250 from $248, reflecting growing confidence in the company's prospects. J.P. Morgan considers Danaher a top pick, citing its strong product portfolio that is relatively shielded from macro pressures.
Analysts are particularly optimistic about Danaher's bioprocessing strength, which is expected to help the company withstand macro headwinds. The company's strategic focus on bioprocessing and its recovery in China are seen as key drivers for future growth. Some analysts project 5-6% core growth for the business in 2026 if bioprocessing demand continues to pick up. Despite Wells Fargo cutting its target price to $205 from $210, the overall sentiment remains positive, with expectations of solid growth in the coming quarters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.